AEON Biopharma (AEON) details major stock unit grants to officer

Rhea-AI Filing Summary

AEON Biopharma, Inc. reported that its principal accounting officer, Jennifer Sy, acquired Class A common stock through equity awards. On February 17, 2026, she received an award of 575,000 restricted stock units that vest in substantially equal installments over four years, subject to continued service. On March 4, 2026, 925,925 previously granted cash-settled restricted stock units from May 21, 2025 were modified to be settled in stock instead of cash, while retaining the same four-year vesting schedule.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sy Jennifer

Role PRINCIPAL ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	925,925	$0.00	--
Grant/Award	Class A Common Stock	575,000	$0.00	--

Holdings After Transaction: Class A Common Stock — 1,501,176 shares (Direct)

Footnotes (1)

1. Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sy Jennifer

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRINCIPAL ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	02/17/2026		A		575,000	A	$0(1)	575,251	D
Class A Common Stock(2)	03/04/2026		A		925,925	A	$0(2)	1,501,176	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

2. Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

	/s/ Alexander Wilson, as Attorney-in-Fact, for Jennifer Sy	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AEON Biopharma (AEON) report for Jennifer Sy?

AEON Biopharma reported that principal accounting officer Jennifer Sy acquired Class A common stock through two equity awards, including a new 575,000-unit restricted stock grant and a modification of 925,925 existing cash-settled units into stock-settled units, both vesting over four years.

How many AEON Biopharma shares were involved in Jennifer Sy’s latest Form 4?

The filing shows equity awards linked to 575,000 newly granted restricted stock units and 925,925 previously granted units changed from cash-settled to stock-settled. All units relate to Class A Common Stock of AEON Biopharma, Inc. and vest over four years.

What are the vesting terms of Jennifer Sy’s restricted stock units at AEON Biopharma (AEON)?

Both awards vest in substantially equal installments on each of the first, second, third and fourth anniversaries of their respective grant dates, subject to continued service. This applies to the 575,000 units granted in 2026 and the 925,925 units originally granted in 2025.

What change was made to Jennifer Sy’s 2025 AEON Biopharma restricted stock units?

Restricted stock units originally granted on May 21, 2025 as cash-settled were modified on March 4, 2026 so that 925,925 units will now be settled in stock instead of cash, while maintaining their existing four-year vesting schedule and service requirement.

Does the AEON Biopharma Form 4 show open-market buying or selling by Jennifer Sy?

The Form 4 reflects grant and modification transactions coded as acquisitions, not open-market purchases or sales. They represent equity compensation: a new award of 575,000 restricted stock units and conversion of 925,925 cash-settled units into stock-settled units.